文献速递临床试验与 GCP基础与转化研究

交泰丸治疗心肾不交型失眠症状:随机双盲安慰剂对照试验方案

Jiao-tai-wan for insomnia symptoms caused by the disharmony of the heart and kidney: a study protocol for a randomized, double-blind, placebo-controlled trial.
PubMed 文献 · Trials · 2020-05-15

本研究为随机双盲安慰剂对照预试验,计划纳入124例心肾不交型失眠症状受试者,等比例随机分入交泰丸组或安慰剂组,每日服药两次、疗程1周。主要结局为匹兹堡睡眠质量指数(PSQI)从基线至干预结束的平均变化,同时评估多导睡眠图、1H-磁共振波谱、心肾不交评分及血清腺苷和褪黑素水平与安全性。

要点

  • 交泰丸组与安慰剂组按1:1随机,每日两次、疗程1周。
  • 主要结局为PSQI从基线至干预结束的平均变化。
  • 次要结局含多导睡眠图、1H-MRS、心肾不交评分及血清腺苷和褪黑素。

核心结论

  • 本研究旨在确认交泰丸对心肾不交型失眠症状的疗效并监测其安全性。

研究设计与样本

  • 随机、双盲、安慰剂对照预试验,计划纳入124例失眠症状受试者,等比例分为交泰丸组与安慰剂组。
  • 受试者每日服用交泰丸或安慰剂颗粒两次,疗程1周,数据于基线和药物干预结束时采集。

关键数值与推荐

  • 主要结局指标为PSQI从基线至药物干预结束的平均变化。
  • 次要结局包括多导睡眠图睡眠参数、1H-MRS评估、心肾不交评分系统评分及血清腺苷和褪黑素水平。
  • 治疗前后进行实验室检查以评估交泰丸安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Insomnia seriously affects people's normal lives and work. However, effective treatment strategies are scarce. The purpose of this study is to explore the efficacy and safety of Jiao-tai-wan (JTW) for ameliorating insomnia symptoms caused by disharmony of the heart and kidney. DESIGN: This is a randomized, double-blind, placebo-controlled pilot clinical trial. A total of 124 participants suffering from insomnia symptoms will be randomly assigned to the JTW or placebo group in an equal ratio. The participants will be asked to take JTW or placebo granules twice a day for 1 week. All data will be gathered at baseline and at the end of the drug intervention. The primary outcome measures will be the mean change in the Pittsburgh Sleep Quality Index (PSQI) from baseline to the end of the drug intervention. Secondary outcome measures will include the altered sleep parameters in polysomnography, 1H-magnetic resonance spectroscopy (1H-MRS) evaluation, the Disharmony of Heart and Kidney Scoring System score, and blood tests, including the levels of serum adenosine and melatonin. A laboratory test will be taken before and after treatment to assess the safety of JTW. DISCUSSION: The outcomes of this study will confirm the efficacy of JTW for the treatment of insomnia symptoms and will also be used to monitor the safety of JTW. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR1800019239. Registered on 1st November 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zeng C, Liu X, Hu L, et al. Jiao-tai-wan for insomnia symptoms caused by the disharmony of the heart and kidney: a study protocol for a randomized, double-blind, placebo-controlled trial. Trials. 2020. PMID: 32414414. doi:10.1186/s13063-020-04299-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。